These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25986684)

  • 1. In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
    Schott S; Vallet S; Tower RJ; Noor S; Tiwari S; Schem C; Busch C
    Invest New Drugs; 2015 Aug; 33(4):816-26. PubMed ID: 25986684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
    Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
    J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
    Weinreich J; Schott TC; Königsrainer I; Küper M; Königsrainer A; Schott H
    Anticancer Res; 2012 Oct; 32(10):4299-305. PubMed ID: 23060550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
    Schott H; Goltz D; Schott TC; Jauch C; Schwendener RA
    Bioorg Med Chem; 2011 Jun; 19(11):3520-6. PubMed ID: 21536448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
    Schott S; Wallwiener M; Kootz B; Seeger H; Fehm T; Neubauer H
    Invest New Drugs; 2012 Aug; 30(4):1750-5. PubMed ID: 21604021
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytotoxicity of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluor-2'-deoxyuridine against human melanoma cells.
    Schott S; Niessner H; Sinnberg T; Venturelli S; Berger A; Ikenberg K; Villanueva J; Meier F; Garbe C; Busch C
    Int J Cancer; 2012 Nov; 131(9):2165-74. PubMed ID: 22323315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of poly(d,l-lactide-co-glycolide)-alendronate conjugate nanoparticles on human osteoclast precursors.
    Cenni E; Avnet S; Granchi D; Fotia C; Salerno M; Micieli D; Sarpietro MG; Pignatello R; Castelli F; Baldini N
    J Biomater Sci Polym Ed; 2012; 23(10):1285-300. PubMed ID: 21781381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
    Hussein O; Tiedemann K; Komarova SV
    Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
    Miller K; Eldar-Boock A; Polyak D; Segal E; Benayoun L; Shaked Y; Satchi-Fainaro R
    Mol Pharm; 2011 Aug; 8(4):1052-62. PubMed ID: 21545170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis.
    Liu T; Romanova S; Wang S; Hyun MA; Zhang C; Cohen SM; Singh RK; Bronich TK
    Mol Pharm; 2019 Jul; 16(7):2872-2883. PubMed ID: 31150251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases.
    Miller K; Clementi C; Polyak D; Eldar-Boock A; Benayoun L; Barshack I; Shaked Y; Pasut G; Satchi-Fainaro R
    Biomaterials; 2013 May; 34(15):3795-806. PubMed ID: 23434349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-catechol conjugated prodrug micelles: combining bone targeting and aryl boronate-based pH-responsive drug release for cancer bone-metastasis therapy.
    Zhu J; Huo Q; Xu M; Yang F; Li Y; Shi H; Niu Y; Liu Y
    Nanoscale; 2018 Oct; 10(38):18387-18397. PubMed ID: 30256367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
    Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
    Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate-functionalized porous nano-crystalsomes mitigate osteolysis and consequent inhibition of tumor growth in a tibia-induced metastasis model.
    Shukla RP; Tiwari P; Sardar A; Urandur S; Gautam S; Marwaha D; Tripathi AK; Rai N; Trivedi R; Mishra PR
    J Control Release; 2024 Aug; 372():331-346. PubMed ID: 38844176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2,2-trichloroethyl)phosphate derivatives of 5-fluoro-2'-deoxyuridine and 2',5-difluoro-2'-deoxyuridine as potential dual action anticancer prodrugs.
    Xia Z; Wiebe LI; Miller GG; Knaus EE
    Arch Pharm (Weinheim); 1999 Aug; 332(8):286-94. PubMed ID: 10489539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.
    Salerno M; Cenni E; Fotia C; Avnet S; Granchi D; Castelli F; Micieli D; Pignatello R; Capulli M; Rucci N; Angelucci A; Del Fattore A; Teti A; Zini N; Giunti A; Baldini N
    Curr Cancer Drug Targets; 2010 Nov; 10(7):649-59. PubMed ID: 20578992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
    Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.